The second reported study CANOPY-1, evaluated canakinumab as first-line therapy for locally advanced or metastatic NSCLC in combination with the anti-PD-L1 drug pembrolizumab and platinum-based doublet chemotherapy and similarly did not meet its primary endpoints of PFS and OS [1]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.